FLOPROPIONE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C9H10O4
Molecular Weight	182.1733
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC(=O)C1=C(O)C=C(O)C=C1O

InChI

InChIKey=PTHLEKANMPKYDB-UHFFFAOYSA-N

InChI=1S/C9H10O4/c1-2-6(11)9-7(12)3-5(10)4-8(9)13/h3-4,10,12-13H,2H2,1H3

HIDE SMILES / InChI

Description
Sources: http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf

Flopropione is an antispasmodic agent developed to relieve spasms in patients with hepatobiliary disorders, pancreatitis and urinary calculus. The mode of action is based on the inhibition of catechol-o-methyl-transferase (COMT), resulting in an adrenergic action, and anti-serotonin action. The current marketing status of the drug is unknown and considered to be "discontinued".

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Catechol O-methyltransferase 21 Target ID: P21964 Gene ID: 1312.0 Gene Symbol: COMT Target Organism: Homo sapiens (Human) Sources: http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Biliary dyskinesia 1 Sources: http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf	Primary	Approved 8429	COSPANON Approved Use Antispasmodic effect resulting from the following diseases: Hepatobiliary disorders: biliary dyskinesia, cholelithiasis, cholecystitis, cholangitis and post-cholecystectomy síndrome; Pancreatic disease: pancreatitis Urinary calculus. Launch Date 1.73318406E11
Cholelithiasis 14 Sources: http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf	Primary	Approved 8429	COSPANON Approved Use Antispasmodic effect resulting from the following diseases: Hepatobiliary disorders: biliary dyskinesia, cholelithiasis, cholecystitis, cholangitis and post-cholecystectomy síndrome; Pancreatic disease: pancreatitis Urinary calculus. Launch Date 1.73318406E11
Cholecystitis 12 Sources: http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf	Primary	Approved 8429	COSPANON Approved Use Antispasmodic effect resulting from the following diseases: Hepatobiliary disorders: biliary dyskinesia, cholelithiasis, cholecystitis, cholangitis and post-cholecystectomy síndrome; Pancreatic disease: pancreatitis Urinary calculus. Launch Date 1.73318406E11
Cholangitis 4 Sources: http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf	Primary	Approved 8429	COSPANON Approved Use Antispasmodic effect resulting from the following diseases: Hepatobiliary disorders: biliary dyskinesia, cholelithiasis, cholecystitis, cholangitis and post-cholecystectomy síndrome; Pancreatic disease: pancreatitis Urinary calculus. Launch Date 1.73318406E11
Post-cholecystectomy syndrome 2 Sources: http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf	Primary	Approved 8429	COSPANON Approved Use Antispasmodic effect resulting from the following diseases: Hepatobiliary disorders: biliary dyskinesia, cholelithiasis, cholecystitis, cholangitis and post-cholecystectomy síndrome; Pancreatic disease: pancreatitis Urinary calculus. Launch Date 1.73318406E11
Pancreatitis 16 Sources: http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf	Primary	Approved 8429	COSPANON Approved Use Antispasmodic effect resulting from the following diseases: Hepatobiliary disorders: biliary dyskinesia, cholelithiasis, cholecystitis, cholangitis and post-cholecystectomy síndrome; Pancreatic disease: pancreatitis Urinary calculus. Launch Date 1.73318406E11
Urinary calculus 3 Sources: http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf	Primary	Approved 8429	COSPANON Approved Use Antispasmodic effect resulting from the following diseases: Hepatobiliary disorders: biliary dyskinesia, cholelithiasis, cholecystitis, cholangitis and post-cholecystectomy síndrome; Pancreatic disease: pancreatitis Urinary calculus. Launch Date 1.73318406E11

PubMed

Title	Date	PubMed
Facilitation of expulsion of ureteral stones by addition of α1-blockers to conservative therapy.	2010 Dec	20604720
Positively charged calcium phosphate/polymer nanoparticles for photodynamic therapy.	2010 Mar	19924519

Patents

Sample Use Guides

In Vivo Use Guide

The usual adult dosage for oral use is 1 to 2 capsules (40-80 mg of flopropione) three times daily after meals.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

FLOPROPIONE

Official Name

English

EPHTANON

Brand Name

English

FLOPROPIONE [MART.]

Common Name

English

Flopropione [WHO-DD]

Common Name

English

FLOPROPIONE [JAN]

Common Name

English

NSC-97909

Code

English

flopropione [INN]

Common Name

English

FLOPROPIONE [MI]

Common Name

English

2',4',6'-TRIHYDROXYPROPIOPHENONE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29698